ZYVERSA THERAPEUTICS


Associated tags: Alport syndrome, Diabetic nephropathy, Focal segmental glomerulosclerosis, Alport, VAR, ASC, Inflammation, Therapy, Pharmaceutical industry, Inflammasome, Patient, NLRP3, Research

Locations: NEW JERSEY, MASSACHUSETTS, BOSTON, AD, UNITED STATES, CALIFORNIA, WESTON, FL, US, NEW YORK

ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes

Retrieved on: 
Thursday, December 7, 2023
NLRP3, DKD, Diabetic nephropathy, Medicine, Plasma, Inflammasome, Survival, Kidney disease, Dialysis, Type 2, Pharmaceutical industry

Diabetic kidney disease (DKD), which affects around 240 million people with Type 2 diabetes worldwide, is the leading cause of end-stage renal disease, which requires dialysis or kidney transplant for survival.

Key Points: 
  • Diabetic kidney disease (DKD), which affects around 240 million people with Type 2 diabetes worldwide, is the leading cause of end-stage renal disease, which requires dialysis or kidney transplant for survival.
  • Data suggest that early DKD intervention with inflammasome inhibitors has potential to attenuate disease progression.
  • In the paper titled, “Correlation Between Plasma NLRP3, IL-1β, and IL-18 and Diabetic Nephropathy in Patients With Type 2 Diabetes,” the authors evaluated the plasma of 152 patients with type 2 diabetes and DKD stratified by stage of disease (stages 1-5) and 30 patients with type 2 diabetes without kidney disease who serve as controls.
  • The data published in Alternative Therapies suggest that early DKD intervention with inflammasome inhibitors has potential to help attenuate disease progression.”

ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

Retrieved on: 
Wednesday, December 6, 2023
Necrosis, Pyroptosis, Cholesterol, Artery, Inflammasome, Plasma, ASC, AIM2, Therapy, Inflammation, Stroke, Lipid, Animal, Patient, Plaque, Pharmaceutical industry

The study published in Diabetes demonstrates that AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.

Key Points: 
  • The study published in Diabetes demonstrates that AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which inhibits multiple inflammasome pathways (including NLRP3 and AIM2) to attenuate initiation and perpetuation of damaging inflammation that is pathogenic in numerous diseases.
  • In the paper titled, “Hematopoietic NLRP3 and AIM2 inflammasomes promote diabetes-accelerated atherosclerosis, but increased necrosis is independent of pyroptosis,” the authors studied mouse models of type 1 diabetes and atherosclerosis.
  • Results are consistent with other animal model studies showing deficiencies in essential inflammasome components, such as NLRP3, AIM2, ASC, and caspase-1, appear to protect against atherosclerosis.

ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock

Retrieved on: 
Thursday, November 30, 2023
Eastern Time Zone, Book, Therapy, Shareholder, Security (finance), Exercise

The Company’s stockholders approved the reverse stock split and the increase in authorized capital stock at the Company’s Annual Meeting of Stockholders held on October 31, 2023.

Key Points: 
  • The Company’s stockholders approved the reverse stock split and the increase in authorized capital stock at the Company’s Annual Meeting of Stockholders held on October 31, 2023.
  • As of the Effective Time, every 35 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock.
  • No fractional shares will be issued as a result of the reverse stock split; rather, the Company will issue an additional fraction of a share of common stock to round the number of shares to the nearest whole share, so no stockholder will hold fractional shares following the reverse stock split.
  • Registered stockholders holding pre-reverse stock split shares of common stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares.

ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Research, GLP, Therapy, Toxicology, IND, Inflammasome, Clinical trial, Cholesterol, Tissue, Patient, ASC, Lipid, Marketing, VAR, Growth, NLRP3, Diabetic nephropathy, DKD, Government, Inflammation, Pharmaceutical industry, Vaccine, Cryptocurrency

WESTON, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today provides a corporate update, and reports financial results for the third quarter of 2023 ending September 30, 2023.

Key Points: 
  • WESTON, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today provides a corporate update, and reports financial results for the third quarter of 2023 ending September 30, 2023.
  • “The third quarter of 2023 marks substantial progress toward meeting a key milestone at ZyVersa, initiation of the first clinical trial with Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease, planned for Q1-2024.
  • Since its inception in 2014 through September 30, 2023, ZyVersa has not generated any revenue and has incurred significant operating losses and negative cash flows from its operations.
  • The net loss improvement was primarily due to lower costs incurred in connection with our research and development programs.

Thinking about buying stock in Visa Inc, Delta Air Lines, Barnes & Noble Education, Zyversa Therapeutics, or BAIYU Holdings?

Retrieved on: 
Thursday, December 7, 2023
Multimedia

Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.

Key Points: 
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
  • InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
  • We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model

Retrieved on: 
Thursday, November 9, 2023
Colon, ASC, Gastrointestinal tract, Diarrhea, IL-6, Cytokine, NLRP3, DSS, Inflammation, Research, Inflammatory bowel disease, Quality of life, IBD, Therapy, Patient, Inflammasome, Super Meat Boy, Gum arabic, Pharmaceutical industry, Financial adviser

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract affecting 1 in 100 Americans (around 2.4 million people) that can lead to disabling bowel symptoms and progressive bowel damage.

Key Points: 
  • Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract affecting 1 in 100 Americans (around 2.4 million people) that can lead to disabling bowel symptoms and progressive bowel damage.
  • NLRP3 inhibition in the IBD animal model:
    Inhibited NLRP3 inflammasome signaling in the colon, resulting in significantly reduced levels of the pro-inflammatory cytokines IL-1b, IL-6, and TNF-α.
  • The inhibition of NLRP3 reverses the IBD-like symptoms in DSS-induced mice, which the regulatory effects on gut microbiota might mediate.
  • “The research published in the Biomedical Journal provides support for inflammasome inhibition as a promising treatment option for IBD.

ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation

Retrieved on: 
Monday, November 6, 2023
Inflammasome, Policy, Biomass, Inflammation, ASC, Kidney, NLRP3, Air pollution, Research, Journal, Security, Chronic kidney disease, Acute kidney injury, Cell death, Particulates, Kidney disease, Therapy, Super Meat Boy, Disability, Fire, Pyroptosis, Pharmaceutical industry, Vaccine, Ecotoxicology

ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which can inhibit up to 12 different inflammasomes (including NLRP3 inflammasomes) and their associated ASC specks which perpetuate damaging inflammation.

Key Points: 
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which can inhibit up to 12 different inflammasomes (including NLRP3 inflammasomes) and their associated ASC specks which perpetuate damaging inflammation.
  • Inhibiting the inflammasome NLRP3 pathway, including downstream caspase-1, rescued the kidneys from PM2.5-induced cell death.
  • The authors stated, “We further provided evidence that NLRP3-mediated pyroptosis plays critical roles in the progression of kidney injury induced by PM2.5 exposure.
  • Inhibiting the activation of NLRP3 inflammasome can remarkably protect the renal tubular epithelial cells from PM2.5-induced proptosis.” To read the article, Click Here .

ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neur

Retrieved on: 
Wednesday, November 1, 2023
Intellectual disability, Inflammasome, EAE, ASC, Mouse, NLRP3, Microglia, Neuroprotection, Phenotype, Inflammation, Research, Brain, Neurotoxicity, Neuroinflammation, Immunomodulation, M1, Molecular neuroscience, Multiple sclerosis, Spinal cord, Astrocyte, Disability, Therapy, Neuroscience, Super Meat Boy, MS, Central nervous system, Pharmaceutical industry

ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.

Key Points: 
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • Key findings showed that NLRP3 inflammasome inhibition:
    Ameliorated pathological changes in the spinal cord and neuron damage in the brain of MS mice.
  • “It is encouraging that the research published in Molecular Neurobiology substantiates our published MS data with Inflammasome ASC Inhibitor IC 100, providing support for its use as a potential therapeutic option.
  • By inhibiting ASC, IC 100 blocks formation of NLRP3 and other types of inflammasomes to block initiation of the inflammatory cascade.

ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease

Retrieved on: 
Wednesday, October 25, 2023
Inflammasome, HADHA, Plasma, Mitochondrion, ASC, Pulmonary fibrosis, Myocardial injury after non-cardiac surgery, Obesity, Human, Inflammation, Research, Mouse, Cardiac fibrosis, Scar, Magnetic resonance imaging, Therapy, Super Meat Boy, Cardiovascular disease, Pharmaceutical industry, Meat, NLRP3, Diabetes

Inflammasome ASC localized in the heart’s mitochondria participates in NLRP3 inflammasome formation and activation based on mouse data.

Key Points: 
  • Inflammasome ASC localized in the heart’s mitochondria participates in NLRP3 inflammasome formation and activation based on mouse data.
  • “The research published in Diabetes demonstrates that ASC in the heart’s mitochondria facilitates NLRP3 inflammasome assembly and activation leading to damaging inflammation and myocardial fibrosis associated with obesity.
  • By inhibiting ASC, IC 100 blocks formation of NLRP3 and other types of inflammasomes to block initiation of the inflammatory cascade.
  • To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here .

ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function

Retrieved on: 
Wednesday, October 18, 2023
ASC, Hypertrophy, Kidney, Inflammation, Research, Journal, Mouse, Enlargement, Chronic kidney disease, Glomerulosclerosis, Disease, Kidney disease, Focal segmental glomerulosclerosis, Scar, Genetic distance, Podocyte, Therapy, FSGS, Inflammasome, Glomerulus, Super Meat Boy, Pharmaceutical industry, Ageing, NLRP3

Age-related inflammasome signaling and its effects are compounded in the presence of kidney disease, leading to poorer outcomes.

Key Points: 
  • Age-related inflammasome signaling and its effects are compounded in the presence of kidney disease, leading to poorer outcomes.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which can inhibit up to 12 different inflammasomes (including NLRP3 inflammasomes) and their associated ASC specks which perpetuate damaging inflammation.
  • Data demonstrate a critical role for NLRP3 inflammasomes in age-related kidney deterioration, which is exacerbated in the presence of kidney disease.
  • NLRP3 inflammasome signaling and its effects on podocytes may be a critical contributor to a lower threshold for developing kidney disease in older people.